Arthritis Research & Therapy (Jun 2021)

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

  • Michelle L. M. Mulder,
  • Tamara W. van Hal,
  • Mark H. Wenink,
  • Hans J. P. M. Koenen,
  • Frank H. J. van den Hoogen,
  • Elke M. G. J. de Jong,
  • Juul M. P. A. van den Reek,
  • Johanna E. Vriezekolk

DOI
https://doi.org/10.1186/s13075-021-02545-4
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Twenty to thirty percent of psoriasis (Pso) patients will develop psoriatic arthritis (PsA). Detection of Pso patients that are (at risk for) developing PsA is essential to prevent structural damage. We conducted a systematic search of five bibliographic databases, up to May 2020. We searched for studies assessing markers (clinical, laboratory, genetic) associated with the development or presence of PsA in Pso patients. Study selection and quality assessment of the included studies was performed, followed by a qualitative best evidence synthesis to determine the level of evidence for a marker and its association with concomitant/developing PsA in Pso. Overall, 259 possible markers were identified in 119 studies that met the inclusion criteria. Laboratory markers related to inflammation and bone metabolism reached a strong level of evidence for the association (not prediction) of PsA in Pso. Only CXCL10 showed strong evidence for a positive predictive value for PsA in Pso. The importance of timely detecting PsA in a Pso population, and finding more (bio)markers contributing to early detection, remains high.

Keywords